7 research outputs found
Headache during airplane travel (āairplane headacheā): first case in Greece
Headache related to airplane flights is rare. We describe a 37-year-old female patient with multiple intense, jabbing headache episodes over the last 3Ā years that occur exclusively during airplane flights. The pain manifests during take-off and landing, and is located always in the left retro-orbital and frontotemporal area. It is occasionally accompanied by dizziness, but no additional symptoms occur. Pain intensity diminishes and disappears after 15ā20Ā min. Apart from occasional dizziness, no other symptoms occur. The patient has a history of tension-type headache and polycystic ovaries. Blood tests and imaging revealed no abnormalities. Here, we present the first case in Greece. We review the current literature on this rare syndrome and discuss on possible pathophysiology and the investigation of possible co-factors such as anxiety and depression
Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO)
Background The benefit of intravenous (i.v.) tissue plasminogen
activator (tPA) in acute ischemic stroke (IS) is attributable to lysis
of thrombus and restoration of perfusion to ischemic but not yet
infarcted brain.
Aims Our multicentre collaborative group prospectively implemented a
protocol for transcranial Doppler assessment of intracranial
recanalization with tPA treatment based on the CLOTBUST clinical trial
(CLOTBUST-PRO). We aim to determine whether early recanalization (within
1 h from tPA bolus) is independently associated with better 3-month
outcome in patients with intracranial arterial occlusions and correlates
to a shorter time interval elapsed from symptom onset to tPA bolus.
Subjects and methods Consecutive patients with acute IS due to
intracranial arterial occlusions will be treated with standard i.v.-tPA
and continuously monitored with 2 MHz Transcranial Doppler for arterial
recanalization. Early recanalization will be determined with the
previously validated Thrombolysis in Brain Ischemia flow-grading system
within 60 min after tPA bolus. Power calculations are based on the
assumption of alpha=0.05 (two-sided test) and probabilities of
functional independence at 3 months of 0.50 and 0.35 in patients with
early complete recanalization and persisting occlusion, respectively.
Detection of a 15% difference with a power of 0.824 requires an
estimated sample of 480 patients of whom 25% are expected to achieve
early recanalization while 75% will have persisting occlusion at 1 h
after tPA bolus. We also plan to test prespecified secondary hypotheses
within the projected study sample.
Conclusions CLOTBUST-PRO is designed to determine if the timing (within
1 h from tPA bolus) of tPA-induced arterial recanalization is an
independent determinant of 3-month functional recovery. We also seek to
demonstrate that the sooner the tPA is given to stroke patients, the
earlier the recanalization occurs and the greater is the likelihood of
functional independence at 3 months
Rate of Force Development, Muscle Architecture, and Performance in Young Competitive Track and Field Throwers
Loss of BRCC3 Deubiquitinating Enzyme Leads to Abnormal Angiogenesis and Is Associated with Syndromic Moyamoya
Moyamoya is a cerebrovascular angiopathy characterized by a progressive stenosis of the terminal part of the intracranial carotid arteries and the compensatory development of abnormal and fragile collateral vessels, also called moyamoya vessels, leading to ischemic and hemorrhagic stroke. Moyamoya angiopathy can either be the sole manifestation of the disease (moyamoya disease) or be associated with various conditions, including neurofibromatosis, Down syndrome, TAAD (autosomal-dominant thoracic aortic aneurysm), and radiotherapy of head tumors (moyamoya syndromes). Its prevalence is ten times higher in Japan than in Europe, and an estimated 6%ā12% of moyamoya disease is familial in Japan. The pathophysiological mechanisms of this condition remain obscure. Here, we report on three unrelated families affected with an X-linked moyamoya syndrome characterized by the association of a moyamoya angiopathy, short stature, and a stereotyped facial dysmorphism. Other symptoms include an hypergonadotropic hypogonadism, hypertension, dilated cardiomyopathy, premature coronary heart disease, premature hair graying, and early bilateral acquired cataract. We show that this syndromic moyamoya is caused by Xq28 deletions removing MTCP1/MTCP1NB and BRCC3. We also show that brcc3 morphant zebrafish display angiogenesis defects that are rescued by endothelium-specific expression of brcc3. Altogether, these data strongly suggest that BRCC3, a deubiquitinating enzyme that is part of the cellular BRCA1 and BRISC complexes, is an important player in angiogenesis and that BRCC3 loss-of-function mutations are associated with moyamoya angiopathy